Sharechat Logo

Smiles all round at GEN-RBC arbitration

By Phil Boeyen, ShareChat Business News Editor

Friday 31st August 2001

Text too small?
Both Genesis (NZSE: GEN) and Rubicon (NZSE: RBC) say they are happy with an arbitration decision released today relating to future royalty rights and jointly owned intellectual property.

Genesis says the decision confirms previously agreed sharing of any royalties arising from future applications of jointly owned intellectual property and also confirms the rights to develop forestry and non-forestry applications.

The biotech company had previously arranged the agreement with Fletcher Forests but this was handed on to Rubicon following the separation of the Fletcher letter stocks.

GEN boss Dr Jim Watson says the decision is very positive and sets clear guidelines for determining future revenue sharing.

He says it also clarifies the sole rights of Genesis to utilise the joint venture intellectual property for non-forestry applications, particularly in the agricultural and horticultural areas.

Genesis has research projects with various commercial collaborators in these areas.

Rubicon, which owns just under 3% of Genesis, also describes the outcome as very positive.

Chief executive, Luke Moriarty, says the award confirms the rights of Rubicon to receive royalties from both forest and non-forest products developed from that intellectual property.

"The arbitration sets clear guidelines for both companies to move forward in a manner that Rubicon finds very acceptable."

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Rubicon returns to profit as Tenon rides US housing rebound, ArborGen rejigs R and D
Genesis Research directors quit due to lack of funds & communication
Genesis Research has ‘lack of funds’, seeks legal advice on future
Genesis Research halted from trading pending statement
ArborGen buys CellFor for CND $1.1 million, reducing Rubicon's shareholding
Genesis Research calls off proposed merger with Mariposa Health
Rubicon shares jump on fully subscribed rights issue
Rubicon to raise $21m from 1-for-3 rights issue
Rubicon sinks deeper into the red
Kupe earnings bolster Genesis 1H profit by 125%